CardioSolv was recently awarded a Phase I Small Business Initiative for Research (SBIR) grant by the National Science Foundation (NSF) to help us develop our technologies into forms more readily usable by the pharmaceutical and device industries.
Here’s the project summary:
This Small Business Innovation Research Phase I project will explore the development and commercial feasibility of a user-friendly cross-platform computing system for multi-scale tissue and organ cardiac electrophysiology and electromechanics modeling. This system will enable the discovery and development of new approaches to the diagnosis and treatment of cardiac disease and allow virtual exploration of mechanisms of cardiac rhythm disorder and electromechanical dysfunction, from the protein to the entire organ. The proposed system will include capabilities for direct input of cardiac imaging data, including patient MR and CT scans, and for the automatic generation of electrophysiological and mechanical computational meshes of the heart. Users will be able to tailor the behavior of individual components of the system to represent specific cardiac pathologies, targets, and interventions. Simulations will be managed with ease, and a robust cross-platform user-friendly interface will allow effortless visualization of results. Specific Technical Objectives include: 1) Assessing the technical feasibility of assembling an automated pipeline; 2) Assessing the technical feasibility of developing a cross-platform GUI that integrates cardiac electromechanical model assembly, simulation, and analysis; and 3) Testing and refining the prototype system to meet customer needs and utilizing user input to assess the commercial feasibility of the system.
The proposed system represents an enormous paradigm shift in the way cardiac electromechanical simulation is done. It will not only integrate, in one easy-to-use system, cardiac electrical and mechanical function using the most sophisticated cardiac simulation tools ever developed, but intends to make simulation accessible to a very broad aspect of society. Currently, cardiac modeling is used in the exploration of new approaches to the diagnosis and treatment of cardiac disease only in a few academic laboratories. However, cardiac device manufacturing, biotech, and pharmaceutical industries have a significant interest in cardiac tissue and organ modeling. For device companies, it presents an opportunity to develop and test prototype devices and treatment modalities. For pharmaceutical companies, it offers an unrivaled opportunity to quickly screen drugs for pro-arrhythmic effects. It also provides benefits to academic researchers since sophisticated state-of-the-art simulation tools will open new research horizons, particularly translational research projects in personalized medicine. In the long term, CardioSolv’s system is expected to bring cardiac modeling to the patient bedside by becoming a physician’s reference tool for patient-specific diagnostics and optimization of cardiac therapy. Finally, the proposed system is expected to become an effective teaching tool, and part of biomedical and clinical curricula.
Keywords: modeling of cardiac electrophysiology, modeling of cardiac mechanics, virtual research environment, cloud computing, cardiac electromechanical dysfunction, cardiac therapy, personalized medicine, cardiac devices, drug screening, virtual teaching tool